To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells in patients with newly diagnosed high-risk acute myeloid leukemia (AML).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
idarubicin 10-12 mg/m2 for three days
idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
The Affiliated Hospital of the Chinese Academy of Military Medical Science
Beijing, Beijing Municipality, China
RECRUITINGcomplete remission
Time frame: one year
disease-free survival
Time frame: three years
overall survival
Time frame: three years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.